tetano
Editor, Senior Moderator
J Clin Med
. 2022 Jul 1;11(13):3838.
doi: 10.3390/jcm11133838.
Current Effective Therapeutics in Management of COVID-19
Kavya Atluri[SUP] 1 [/SUP], Iris Aimlin[SUP] 2 [/SUP], Shitij Arora[SUP] 3 [/SUP]
Affiliations
Abstract
The current pandemic due to the SARS-CoV-2 virus has caused irreparable damage globally. High importance is placed on defining current therapeutics for Coronavirus Disease 2019 (COVID-19). In this review, we discuss the evidence from pivotal trials that led to the approval of effective therapeutics in the treatment and prevention of COVID-19. We categorize them as effective outpatient and inpatient management strategies The review also attempts to contextualize the efficacy of therapeutics to the emerging variants. Vaccines, which remain the most effective prevention against hospitalization and deaths is not included in this review.
Keywords: Anakinra; COVID-19; Casirivimab plus imdevimab; Sotrovimab; anticoagulation; baricitinib; bebtelovimab; coronavirus disease 2019; corticosteroids; evusheld; molnupiravir; monoclonal antibodies; omicron; paxlovid; remdesivir; therapeutics; timeline; tocilizumab.
. 2022 Jul 1;11(13):3838.
doi: 10.3390/jcm11133838.
Current Effective Therapeutics in Management of COVID-19
Kavya Atluri[SUP] 1 [/SUP], Iris Aimlin[SUP] 2 [/SUP], Shitij Arora[SUP] 3 [/SUP]
Affiliations
- PMID: 35807123
- DOI: 10.3390/jcm11133838
Abstract
The current pandemic due to the SARS-CoV-2 virus has caused irreparable damage globally. High importance is placed on defining current therapeutics for Coronavirus Disease 2019 (COVID-19). In this review, we discuss the evidence from pivotal trials that led to the approval of effective therapeutics in the treatment and prevention of COVID-19. We categorize them as effective outpatient and inpatient management strategies The review also attempts to contextualize the efficacy of therapeutics to the emerging variants. Vaccines, which remain the most effective prevention against hospitalization and deaths is not included in this review.
Keywords: Anakinra; COVID-19; Casirivimab plus imdevimab; Sotrovimab; anticoagulation; baricitinib; bebtelovimab; coronavirus disease 2019; corticosteroids; evusheld; molnupiravir; monoclonal antibodies; omicron; paxlovid; remdesivir; therapeutics; timeline; tocilizumab.